- Home
- BIIB vs TYL Comparison
BIIB vs TYL Comparison
Compare BIIB & TYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TYL
- Stock Information
- Founded
- BIIB 1978
- TYL 1966
- Country
- BIIB United States
- TYL United States
- Employees
- BIIB N/A
- TYL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TYL Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- TYL Technology
- Exchange
- BIIB Nasdaq
- TYL Nasdaq
- Market Cap
- BIIB 25.1B
- TYL 27.2B
- IPO Year
- BIIB 1991
- TYL N/A
- Fundamental
- Price
- BIIB $150.03
- TYL $611.36
- Analyst Decision
- BIIB Buy
- TYL Strong Buy
- Analyst Count
- BIIB 27
- TYL 13
- Target Price
- BIIB $252.20
- TYL $642.62
- AVG Volume (30 Days)
- BIIB 1.4M
- TYL 288.4K
- Earning Date
- BIIB 02-11-2025
- TYL 02-12-2025
- Dividend Yield
- BIIB N/A
- TYL N/A
- EPS Growth
- BIIB 10.05
- TYL 47.95
- EPS
- BIIB 11.06
- TYL 5.48
- Revenue
- BIIB $9,607,500,000.00
- TYL $2,077,606,000.00
- Revenue This Year
- BIIB N/A
- TYL $10.57
- Revenue Next Year
- BIIB N/A
- TYL $10.43
- P/E Ratio
- BIIB $13.56
- TYL $111.70
- Revenue Growth
- BIIB N/A
- TYL 8.04
- 52 Week Low
- BIIB $149.94
- TYL $397.80
- 52 Week High
- BIIB $268.30
- TYL $638.56
- Technical
- Relative Strength Index (RSI)
- BIIB 25.52
- TYL 46.73
- Support Level
- BIIB $153.69
- TYL $612.92
- Resistance Level
- BIIB $158.20
- TYL $635.48
- Average True Range (ATR)
- BIIB 3.58
- TYL 12.72
- MACD
- BIIB 0.16
- TYL -1.56
- Stochastic Oscillator
- BIIB 0.62
- TYL 10.86
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.